The Raf1/Mek/Erk kinase inhibitor sorafenib is approved for advanced HCC, and it’s noted that the formation of SGs in sorafenib-treated HCC cells correlates with inhibition of translation initiation (Tong et al., 2022). The gene discussed is RAF1; the disease is hepatocellular carcinoma.